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Hürthle cell-predominant thyroid fine needle aspiration
cytology: A four risk-factor model highly accurate in excluding
malignancy and predicting neoplasm
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Abstract
Background: Interpretation of Hürthle cell-predominant cytologies (HCP) is very
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challenging as a majority is diagnosed as indeterminate. Prior studies have reported
various cytologic features to help distinguish non-neoplastic (NN) from neoplastic
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and malignant lesions but had contradicting results. Our aim was to identify risk fac-
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clinical and ultrasound findings.
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tors predictive of neoplasm and/or malignancy by correlating cytologic features with
Methods: Sixty-nine HCP cases with surgical follow-up were identified, including
35 NN, 20 adenomas, and 14 carcinomas. Ultrasound data were recorded utilizing
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Thyroid Imaging Reporting and Data System (TI-RADS) and American Thyroid Association (ATA) scoring systems. Sixteen cytologic criteria were evaluated and semiquantitatively scored. Data were assessed by univariable, multivariable and stepwise
logistic regression analysis; and statistical significance achieved at P-value <0.05.
Results: On univariable analysis, significant predictors of neoplasm were high cellularity, isolated single cells, absent colloid, non-uniform HC population (anisonucleosis),
larger nodule size, and higher ATA score. Large-cell dysplasia and transgressing blood
vessels were not found to be significant factors. Multivariable analysis identified a
combination of four risk factors (high cellularity, anisonucleosis, absent colloid, and
size ≥2.9 cm) that was associated with neoplasm in 10/11 patients. None of 15
patients with zero or 1 out of 4 risk factors had malignancy or neoplasm on followup. This model also significantly outperformed ATA and TI-RADS scoring systems.
Conclusion: In the absence of four or three risk factors, the model excluded malignancy and neoplasm in all patients. The presence of all four factors predicted neoplasm and malignancy in 91% and 46% of cases, respectively.
KEYWORDS
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1

|

I N T RO DU CT I O N

aspirates, and inconsistent to absent incorporation of clinical and
imaging features.

Hürthle/oncocytic cells (HCs) are a common finding in thyroid fine

The Thyroid Imaging Reporting and Data System (TI-RADS) and

needle aspiration cytology (FNA) and can be associated with benign

the American Thyroid Association (ATA) ultrasound classification sys-

and malignant neoplasms, as well as non-neoplastic (NN) conditions

tems were recently introduced and are currently widely utilized in the

such as oncocytic metaplasia associated with nodular goiter and lym-

preoperative evaluation of thyroid nodules.11–13 Some studies have

phocytic thyroiditis. Major differential diagnostic considerations

shown that TI-RADS and ATA scoring systems can be particularly

include NN disease, Hürthle cell adenoma (HCA), Hürthle cell carci-

helpful in the management of thyroid nodules with indeterminate

noma (HCC), and papillary thyroid carcinoma (PTC) with oncocytic

cytology.14 However, correlation of cytologic features of HCP aspi-

features. FNAs showing admixture of HCs and benign non-HC com-

rates with ATA and TI-RADS scores and clinical features has not been

ponents such as abundant colloid, many lymphocytes, and/or thyroid

previously reported.

normo-follicular cells are usually diagnosed as NN, pose no diagnostic

The aim of the current study was to identify a combination of

challenge, and placed in the “benign” category (B-2) of the Bethesda

cytologic, ultrasound, and clinical features that would allow us to con-

system for reporting thyroid cytology (TBSRTC).1 However, FNAs

struct a statistically significant risk-factor model that can better pre-

consisting exclusively or almost exclusively of HCs, that is, HC-

dict or exclude the presence of neoplasia and/or malignancy in HCP

predominant (HCP), are diagnostically challenging for the pathologist,

FNAs that are diagnostically challenging, i.e., aspirates that are diag-

as it is often difficult to distinguish neoplastic from NN nodules. HCP

nosed as “indeterminate” by TBSRTC.

FNAs often fall into one of two indeterminate TBSRTC categories:
atypia/follicular lesion of undetermined significance (AUS/FLUS) and
follicular neoplasm/suspicious for follicular neoplasm (FN/SFN).1,2

2

|

MATERIAL AND METHODS

Follow-up studies, however, have shown that risks of malignancy
(ROM) associated with HCP are appreciably lower than those of non-

Under an institutional review board-approved protocol, archival cyto-

HCP, which could potentially lead to increased number of unneces-

pathology files of Cleveland Clinic were searched to identify all poten-

sary surgeries.3

tial

HCP

thyroid

FNAs

diagnosed

between

1/1/2010

and

Molecular studies have been utilized in recent years with

12/31/2014. The distribution of thyroid FNAs over that time was:

intended purpose of increasing the predictive power of indeterminate

total cases: 12108; non-diagnostic: 1333 (11%); benign: 8735 (72%);

4

cytologies, but HCP indeterminate lesions have not been extensively

AUS/FLUS: 874 (7%); FN/SFN: 585 (5%); suspicious for malignancy:

studied.4 Reported negative predictive values (NPV) and positive pre-

227 (2%); Malignant: 354 (3%). Per TBSRTC guidelines,1 Hürthle cell

5,8,9

dictive values (PPV) are 94–96% and 40–46%, respectively.

The

type (HCT) was reported as a subtype of FN/SFN (FN/SFN-HCT), but

major strength of molecular testing is identifying nodules that have a

not as a subtype of AUS/FLUS. FN/SFN-HCT comprised 28% of

high likelihood of being benign, but a major limitation is their low

FN/SFN cases (166/585) and 1.4% of all thyroid FNAs. AUS/FLUS

specificity which results in significant false-positive rates. In addition,

was searched for reports that mentioned “Hürthle” or “oncocytic” in

reflex molecular testing is not performed at many institutions, and an

the diagnosis or comment lines, and that resulted in 23 cases. Of the

indeterminate cytologic diagnosis may either lead to a repeat FNA

total retrieved search of HCP nodules with diagnoses of FN/SFN and

with triage for molecular testing or lobectomy following a repeat inde-

AUS/FLUS (189 cases), only cases that had available ultrasound imag-

terminate diagnosis.

ing and histopathologic correlation were considered for the study

Few previous studies have attempted to evaluate cytologic fea-

(90 cases); slides were available in 69 of those cases. Therefore, the

tures that can help predict neoplasm or malignancy, but there has

final study cohort consisted of 69 HCP aspirates from 69 patients

been limited agreement regarding the usefulness of specific cytologic

(age range 27–86, median 61 years). Distribution of cytologic diagno-

criteria.3,10 This may have been partly due to the small number of

ses, histologic follow-up, risk of malignancy (ROM), and risk of neopla-

cases included in those studies, limited application of statistical analy-

sia (RON) are shown in Table 1. For this study, AUS/FLUS with HCP

sis, dilution of study cohorts by easily diagnosed B-2 category

is referred to as AUS/FLUS-HCT. NN was defined as nodular

TABLE 1

Cyto-histologic correlation of Hürthle cell-predominant cases included in the study

Cytologic diagnosis

Surgical pathology follow-up

TBSRTC categories

# Cases(%)

NN

HCA

HCC

PTC, oncocytic

ROM (%)

RON (%)

AUS/FLUS-HCT

7 (10)

5

1

0

1

14

29

FN/SFN-HCT

62 (90)

30

19

9

4

22

52

Totals

69

35

20

9

5

20

49

Abbreviations: AUS/FLUS-HCT, atypia/follicular lesion of undetermined significance- Hürthle cell type; FN/SFN-HCT, follicular neoplasm/suspicious for
follicular neoplasm- Hürthle cell type; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma; NN, Non-neoplastic; PTC, Papillary thyroid carcinoma;
ROM, risk of malignancy; RON, risk of neoplasia; TBSRTC, the Bethesda System for Reporting Thyroid Cytology.
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hyperplasia and/or lymphocytic thyroiditis associated with oncocytic

Sixteen previously reported cytologic criteria15–23 were evaluated

metaplasia. Molecular testing was performed on 4 out of 69 cases

in all cases. The cytologic features, their assessment and definitions

(Afirma GEC), and all were resulted as “suspicious.” Follow-up demon-

are presented in Table 2. All criteria were semi-quantitatively scored

strated 3 HCA and 1 NN. Age, sex, and nodule size were documented,

concurrently by 2 Cytopathologists (TME, LY), blinded to final cyto-

and ultrasound imaging was interpreted by an endocrinologist with

logic and histologic diagnoses.

extensive expertise in neck ultrasonography and thyroid neoplasia

Unordered categorical factors were summarized using frequen-

(CN), blinded to FNA diagnoses and surgical outcomes, and data

cies and percentages and were compared between NN, neoplasm and

recorded utilizing ATA and TI-RADS scoring systems.12,13

malignant groups using Pearson chi-square tests or Fisher exact tests

TABLE 2

Cytologic features evaluated in 69 Hürthle cell-predominant nodulesa

Cytologic feature

Evaluation

Definition

Cellularity

Low or high

Low: sparse cellularity
High: moderate to marked cellularity

Percentage of Hürthle cells (≥ 90%)

a

Lower or higher

Percentage of admixed
normo-follicular cells

Lower or higher than 50%

Architecture of Hürthle cells

Predominant flat sheets or threedimensional groups

Microfollicles

< 25% or ≥25%

HCs with repetitive microfollicular pattern

Isolated single cells ≥10%

Absence or presence

Discohesive HCs with intact cytoplasm

Uniformity of Hürthle cell population

Predominant uniform vs. non-uniform
population

Uniform: HCs of similar size, without significant variation of
nuclear shape or size, and without increased N/C ratios.
Non-uniform (anisonucleosis): HCs with diffuse significant
variation in nuclear size (ranging from less than to
greater than twice nuclear size variation) and involving
>50% of HCs. In contrast to large-cell dysplasia (LCD),
hyperchromasia and/or nuclear irregularities are not
required20

Small-cell dysplasia

Absence or presence

Small cells with high N/C ratio (cytoplasmic diameter less
than twice nuclear diameter, with often bland
appearance)19

LCD

Absence or presence

Large cells with at least two times variability in nuclear
size, and typically demonstrating hyperchromasia.
Prominent nucleoli and/or irregular nuclear outlines may
be present.19,24 This feature is usually sporadic in
distribution, in contrast to the diffuse nature of
anisonucleosis

Colloid

Absence or presence
If present, further subcategorized as (a)
scant vs. abundant, and (b) predominately
thin vs. predominately thick

Lymphocytes

Absence or presence
If present further subcategorized as (a) rare
or (b) numerous

Transgressing blood vessels

Absence or presence

Thin delicate capillaries with distinct capillary nuclei
intimately associated with loosely cohesive groups/
sheets of HCs.24

Intracytoplasmic lumens

Absence or presence

Sharply demarcated intracytoplasmic vacuoles that have a
tinctorial quality similar to the slide background

PTC-like nuclear atypia

Absence or presence

Nuclear enlargement with pale/powdery chromatin, and
nuclear irregularities and/or grooves

If present further subcategorized as (a) focal
or (b) diffuse
Cystic changes

Absence or presence

Many background macrophages

Abbreviations: HC, Hürthle cell; LCD, large cell dysplasia; N/C, Nuclear/cytoplasmic.
All aspirates had >50% Hürthle cells. Great majority of cases (66/69, 96%) had >90% Hürthle cells.

a
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TABLE 3

Univariable statistical analysis of predictors of non-neoplastic versus neoplasm
Non-neoplastic (N = 35)

Factor
Age

Total (N = 69)
59.4 ± 12.9

Gender
Male
Female
High cellularity (moderate-marked)
Size (cm)

N
35

Statistics
59.7 ± 12.4

35
25 (36.2)

2.8 ± 1.6

N
34

35

59.0 ± 13.5

17 (48.6)
2.2 ± 1.3

p-value
0.82a1
0.073b

16 (47.1)

26 (74.3)
35

Statistics

34
9 (25.7)

44 (63.8)
45 (65.2)

Neoplasm (N = 34)

18 (52.9)
34
34

28 (82.4)
3.5 ± 1.7

0.003c
<0.001a1

Size ≥2.9 cm

29 (42.0)

35

7 (20.0)

34

22 (64.7)

<0.001c

Hurthle cells >90%

66 (95.7)

35

33 (94.3)

34

33 (97.1)

0.99d

2 (2.9)

35

2 (5.7)

34

0 (0.00)

0.49d

Flat HC sheets

15 (21.7)

35

5 (14.3)

34

10 (29.4)

0.13c

Isolated single cells

30 (43.5)

35

10 (28.6)

34

20 (58.8)

0.011c

Uniform HC population

27 (39.1)

35

18 (51.4)

34

9 (26.5)

0.034c

3 (4.3)

35

0 (0.00)

34

3 (8.8)

0.11d

20 (29.0)

35

8 (22.9)

34

12 (35.3)

0.25c

Normo-follicular Cells ≥50%

Small-cell dysplasia
LCD
Colloid

35

0.003b

34

Absent

47 (68.1)

18 (51.4)

29 (85.3)

Scant

13 (18.8)

9 (25.7)

4 (11.8)

Abundant
Thick
Colloid present (scant/abundant)

9 (13.0)

Rare
Numerous

1 (2.9)

17

13 (76.5)

5

5 (100.0)

0.54d

22 (31.9)

35

17 (48.6)

34

5 (14.7)

0.003c

Lymphocytes
Absent

8 (22.9)

18 (81.8)

35

0.99b

34

61 (88.4)

31 (88.6)

30 (88.2)

7 (10.1)

3 (8.6)

4 (11.8)

1 (1.4)

1 (2.9)

0 (0.00)

Transgressing blood vessels

29 (42.0)

35

14 (40.0)

34

15 (44.1)

0.73c

Intracytoplasmic lumina

12 (17.4)

35

4 (11.4)

34

8 (23.5)

0.18c

Nuclear atypia: PTC-like features
Absent
Focal
Diffuse
Cystic changes

35

0.65b

34

58 (84.1)

30 (85.7)

28 (82.4)

9 (13.0)

5 (14.3)

4 (11.8)

2 (2.9)
10 (14.5)

Malignancy risk by ATA

0 (0.00)
35

6 (17.1)

35

2 (5.9)
34

4 (11.8)

0.006b

34

Very low suspicion risk

21 (30.4)

14 (40.0)

Low suspicion risk

22 (31.9)

14 (40.0)

8 (23.5)

Intermediate suspicion risk

17 (24.6)

5 (14.3)

12 (35.3)

High suspicion risk

9 (13.0)

TI-RADS
TR2 not suspicious

7 (20.6)

2 (5.7)
35

0.73d

7 (20.6)
0.18b

34

5 (7.2)

2 (5.7)

3 (8.8)

TR3 Mildly suspicious

19 (27.5)

12 (34.3)

7 (20.6)

TR4 Moderately suspicious

29 (42.0)

16 (45.7)

13 (38.2)

TR5 Highly suspicious

16 (23.2)

5 (14.3)

11 (32.4)

Note: Statistics presented as Mean ± SD, N (column %). Bold italic denotes statistically significant values.
Abbreviation: ATA, American Thyroid Association Imaging scoring system; HC, Hürthle cell; TI-RADS, Thyroid Imaging Reporting and Data System.
p-values (statistically significant values are in bold).
a1
t-test.
b
Wilcoxon Rank Sum test.
c
Pearson's chi-square test.
d
Fisher's Exact test.
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TABLE 4

Univariable statistical analysis of predictors of benign versus malignancy
Benign (N = 55)

Malignant (N = 14)

Factor

Total (N = 69)

N

Statistics

N

Statistics

Age

59.4 ± 12.9

55

58.4 ± 13.1

14

63.1 ± 11.8

Gender

55

Male

25 (36.2)

Female

44 (63.8)

0.23a1
0.57b

14
19 (34.5)

p-value

6 (42.9)

36 (65.5)

8 (57.1)

High cellularity

45 (65.2)

55

34 (61.8)

14

11 (78.6)

0.35d

Size (cm)

2.8 ± 1.6

55

2.5 ± 1.3

14

4.1 ± 2.1

0.012a2

Size ≥2.9 cm

29 (42.0)

55

19 (34.5)

14

10 (71.4)

0.013c

Hurthle cells ≥90%

66 (95.7)

55

53 (96.4)

14

13 (92.9)

0.50d

2 (2.9)

55

2 (3.6)

14

0 (0.00)

0.99d

Flat HC sheets

15 (21.7)

55

10 (18.2)

14

5 (35.7)

0.17d

Isolated single cells

30 (43.5)

55

20 (36.4)

14

10 (71.4)

0.018c

27 (39.1)

55

24 (43.6)

14

3 (21.4)

0.13c

3 (4.3)

55

3 (5.5)

14

0 (0.00)

0.99d

20 (29.0)

55

16 (29.1)

14

4 (28.6)

0.99d

Normo-follicular Cells ≥50%

Uniform HC population
Small-cell dysplasia
LCD
Colloid

55

0.094b

14

Absent

47 (68.1)

35 (63.6)

12 (85.7)

Scant

13 (18.8)

11 (20.0)

2 (14.3)

Abundant
Thick
Colloid present (scant/abundant)

9 (13.0)

Rare
Numerous

0 (0.00)

20

16 (80.0)

2

2 (100.0)

0.99d

22 (31.9)

55

20 (36.4)

14

2 (14.3)

0.20d

Lymphocytes
Absent

9 (16.4)

18 (81.8)

55

0.23b

14

61 (88.4)

50 (90.9)

11 (78.6)

7 (10.1)

4 (7.3)

3 (21.4)

1 (1.4)

1 (1.8)

0 (0.00)

Transgressing blood vessels

29 (42.0)

55

23 (41.8)

14

6 (42.9)

0.94c

Intracytoplasmic lumina

12 (17.4)

55

9 (16.4)

14

3 (21.4)

0.70d

Nuclear atypia: PTC-like features
Absent
Focal
Diffuse
Cystic changes

55

0.51b

14

58 (84.1)

47 (85.5)

11 (78.6)

9 (13.0)

7 (12.7)

2 (14.3)

2 (2.9)
10 (14.5)

Malignancy risk by ATA

1 (1.8)
55

8 (14.5)

55

1 (7.1)
14

2 (14.3)

<0.001b

14

Very low suspicion risk

21 (30.4)

21 (38.2)

0 (0.00)

Low suspicion risk

22 (31.9)

19 (34.5)

3 (21.4)

Intermediate suspicion risk

17 (24.6)

13 (23.6)

4 (28.6)

High suspicion risk

9 (13.0)

TI-RADS
TR2 Not Suspicious

2 (3.6)
55

0.99d

7 (50.0)
0.004b

14

5 (7.2)

5 (9.1)

0 (0.00)

TR3 Mildly suspicious

19 (27.5)

17 (30.9)

2 (14.3)

TR4 Moderately suspicious

29 (42.0)

25 (45.5)

4 (28.6)

TR5 Highly suspicious

16 (23.2)

8 (14.5)

8 (57.1)

Note: Statistics presented as Mean ± SD, N (column %).
Abbreviations: ATA, American Thyroid Association Imaging scoring system; HC, Hürthle cell; TI-RADS, Thyroid Imaging Reporting and Data System.
a1
t-test.
a2
Satterthwaite t-test.
b
Wilcoxon rank sum test.
c
Pearson's chi-square test.
d
Fisher's exact test.
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when events were rare. Ordered categorical factors were summarized

their low frequencies and were removed as candidate risk predic-

similarly and compared using Wilcoxon rank sum tests. Continuous

tors. Multivariable logistic regression models predicting neoplasm

measures were summarized using means and standard deviations and

or malignancy were fit. Model selection was performed using penal-

compared using two-sample t-tests. Receiver operating characteristic

ized regression models with variable selection performed with

(ROC) curve analysis was performed to identify the best size cutoff

LASSO methods. Analysis was performed using SAS software (ver-

point for neoplasm and malignancy, and to compare the best fit model

sion 9.4; Cary, NC). Statistical significance was evaluated based on

against ATA and TI-RADS scoring rules. In multivariable modeling,

P-value <0.05.

multicollinearity was checked using variance inflation factors and
condition indices. Normo-follicular cell percentage, lymphocytes,

3

and small-cell dysplasia were found to be collinear, likely due to

RE SU LT S

|

On univariable analysis, HCP aspirates derived from neoplasms (carciTABLE 5

noma and HCA) were significantly less likely to have a uniform cell

Multivariable four-risk factor model for neoplasm

population, but more likely to have higher cellularity, isolated single

Risk factor

OR (95% CI)

p-value

cells, absent colloid, larger nodule size, and higher ATA ultrasound

Colloid absent

13.38 (2.60, 68.71)

0.002

malignancy risk levels (Table 3). Malignant nodules were more likely to

Size ≥2.9 cm

8.55 (2.14, 34.22)

0.002

be of larger size, have isolated single cells, and higher ATA and TI-

Non-uniform Hurthle
cell population

4.01 (1.04, 15.52)

0.044

RADS ultrasound malignancy risk scores, when compared to benign

Cellularity high

6.65 (1.54, 28.67)

0.011

lesions (NN and HCA) (Table 4). By ROC analysis, a size cutoff of
2.9 cm or larger provided the best prediction for neoplasm, with a
sensitivity of 65% and specificity of 80%; this factor was then utilized

Abbreviations: OR, odds ratio; CI, confidence interval; and Cstatistic = 0.879.

T A B L E 6 Number of risk factors and
follow-up histologic diagnoses

in subsequent multivariable modeling. The best size cut-off point for

Histologic follow-up
Number of risk factors

Total

Non-neoplastic

HCA

4/4 risk factors

11

1

5

0/4 risk factors

3

3

0

1/4 risk factors

12

12

0 and 1 risk factora

15

15

0

Malignant

ROM (%)

RON (%)

5

46

91

0

0

0

0

0

0

0

0

0

Abbreviations: HCA, Hürthle cell adenoma; ROM, risk of malignancy; and RON, risk of neoplasia.
Sum of data for zero and one risk factor (four- and three-risk factors absent).

a

F I G U R E 1 This case had 4 risk
factors. (A) FNA of a 3.5 cm nodule with
hypercellularity, non-uniform Hürthle cell
population (anisonucleosis), and absent
colloid (Papanicolaou stain x 400). (B)
There was focal large cell dysplasia
(Papanicolaou stain x 400). C) Follow-up
thyroidectomy revealed an angioinvasive
Hürthle cell carcinoma (H&E stain x 200)
[Color figure can be viewed at
wileyonlinelibrary.com]
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F I G U R E 2 A) This 4.3 cm nodule
showed hypercellularity, non-uniform
population, and absent colloid (four risk
factors) (Papanicolaou stain x 400).
Follow-up demonstrated Hürthle cell
adenoma (HCA) (not shown). (B and C)
This nodule was of low cellularity and had
3 risk factors: size of 3.8 cm nodule, nonuniform population, and absent colloid
(not shown). (B) There was focal nuclear
irregularity and atypia raising the
possibility of papillary thyroid carcinoma
(PTC)-like changes (ThinPrep,
Papanicolaou stain x 600). (C) Follow-up
histology revealed a HCA with slight
nuclear irregularities, but no evidence of
PTC (H&E stain x 600) [Color figure can
be viewed at wileyonlinelibrary.com]

F I G U R E 3 (A) This nodule had zero
out of 4 risk factors, including uniform cell
population and scant colloid. Cytology
was signed out as SFN-HCT, but
histologic follow-up demonstrated
nodular hyperplasia (NH) (not shown).
(Papanicolaou stain x 400). (B)–(D): This is
another case that had 0/4 risk factors
including a predominately uniform
Hurthle cell population (B) with only
focal/scattered anisonucleosis
(C) (Papanicolaou stain x 400). The FNA
was signed out as SFN-HCT. Histologic
follow-up (D) showed NH with random
nuclear/endocrine atypia (H&E stain
x200) [Color figure can be viewed at
wileyonlinelibrary.com]

malignancy was also ≥2.9 cm, with a sensitivity of 71%, and a specific-

compared to NN. Ten of 11 patients with all 4 risk factors had neo-

ity of 66%.

plasm (RON: 90.9%) (Table 6), and 5 of those had HCC (ROM:

Multivariable model selection for neoplasm identified cellularity,

45.5%) (Figures 1 and 2). For malignancy, sensitivity, specificity, PPV,

nodule size, isolated single cells, uniformity of HC population, and

and NPV were 35.7%, 89.1%, 45.5%, and 84.5%, respectively. None

colloid as potential predictors. Given that a predictive model for data

of the 3 patients with zero risk factors had neoplasm or malignancy,

this size can only use 3 or 4 effects, further reductions based on

and none of 12 patients with one risk factor had neoplasm or malig-

level of statistical significance was performed, and a final predictive

nancy (Table 6) (Figures 3-6). Therefore, in utilizing this model, the

model based on 4 risk factors was constructed. FNAs with high cellu-

absence of 3 or 4 risk factors was associated with sensitivity, speci-

larity, size of ≥2.9 cm, non-uniform HC population, and absent col-

ficity, PPV, and NPV of 100%, 27.3%, 25.9%, and 100%, respec-

loid were at greater risk of being neoplastic (Table 5). This predictive

tively. Compared against ATA and TI-RADS scoring systems, this

model provided a C-statistic of 0.88, indicating that the model was

four-risk factor model performed significantly better at predicting

successful 88% of the time in assigning a higher risk for neoplasm

neoplasm (Table 7).
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F I G U R E 4 (A) This aspirate had
prominent transgressing blood vessels
(TBV), large-cell dysplasia (LCD), and
isolated single cells in the background
(Papanicolaou stain x 400). The FNA was
signed out as SFN-HCT. (B) Follow-up
histology revealed nodular hyperplasia
with oncocytic metaplasia (H&E stain
x100). Prominent vascularity within the
hyperplastic nodule explains the presence
of TBV in the FNA (inset) [Color figure
can be viewed at wileyonlinelibrary.com]

F I G U R E 5 A-B) This case had one out
of 4 risk factors. It's an FNA of a 2.3 cm
nodule that was of low (sparse) cellularity
and showed uniform Hurthle cell
population (A) and absent colloid
(Papanicolaou stain x 400). Follow-up
histology revealed a hyperplastic nodule
(HN) with oncocytic metaplasia (B).
Although this HN had a macrofollicular
architecture on histology, there was
absent colloid on the corresponding FNA
(H&E stain x200). C) This is another FNA
where the only risk factor was
hypercellularity, as the Hürthle cells had
uniform appearance and there was scant
colloid present elsewhere (Papanicolaou
stain x 200). Cytology was signed out as
SFN-HCT, and histologic follow-up
showed nodular hyperplasia (not shown)
[Color figure can be viewed at
wileyonlinelibrary.com]

4

|

DISCUSSION

suggested to distinguish NN from neoplastic and malignant HCP
lesions, but no set of criteria has been widely accepted.21 Many of

The cytologic evaluation of HCP FNAs can be quite challenging, as it's

those studies evaluated HC-rich cytologies that included diagnosti-

often difficult to distinguish NN from HCA or carcinoma. Further-

cally non-challenging B-2 cases. However, the goal of our study was

more, follow-up studies have shown that ROMs associated with HCP

to identify a more specific combination of cytologic, ultrasound, and

FNAs are appreciably lower than those of non-HCP (0–30% for AUS-

clinical features that would help us better predict or exclude the pres-

HCT [median 15%], and 14–45% for FN/SFN-HCT [median 23%],

ence of neoplasia and/or malignancy in diagnostically challenging

compared to 10–30% for AUS/FLUS, and 25–40% for FN/SFN.3

cases that were diagnosed as “indeterminate” by TBSRTC.

These lower ROM rates are very similar to those calculated in our

We correlated 16 previously reported cytomorphologic features

cohort study: 14% and 21% for AUS/FLUS-HCT and FN/SFN-HCT,

with clinical parameters and ATA and TI-RADS ultrasound scoring sys-

respectively (Table 1). Many cytologic features have been previously

tems, individually and combined, and with surgical outcome. We then

432

YUAN ET AL.

F I G U R E 6 A-B) This nodule
demonstrated only one out of four risk
factors: non-uniform Hurthle cell
population, but had low cellularity, scant
colloid, and a size of 1.8 cm. (A) There
was, however, a prominent microfollicular
arrangement and rare background
lymphocytes (Diff Quik stain x 400). The
cytology was signed out as
SFN/FN. (B) Follow-up lobectomy
showed nodular lymphocytic thyroiditis
with areas of microfollicular architecture
[Color figure can be viewed at
wileyonlinelibrary.com]

T A B L E 7 Comparison of four-risk factor model to ultrasound
imaging scoring systems in predicting neoplasm

inflammation, non-macrofollicular architecture (single isolated cells,
microfollicles, or 3-D groups), and TBV correctly identified HC neoplasms in 86% of their cases.16 Some authors reported that
tures, were associated with neoplasia and malignancy.15–21,23,26 Our

AUC (95% CI)

P-value (vs. four-risk
factor model)

Four-risk
factor model

0.879 (0.799, 0.960)

N/A

ATA

0.690 (0.568, 0.812)

0.016

port other criteria previously cited to be diagnostic of neoplasia or

TI-RADS

0.590 (0.461, 0.720)

<0.001

malignancy. Although isolated single cells were found to be associated

anisonucleosis, hypercellularity, and absent colloid, among other feadata corroborated some of the above-listed criteria, but did not sup-

Abbreviations: ATA, American Thyroid Association ultrasound
classification system; AUC, area under curve; CI, confidence interval; N/A,
Not applicable; TI-RADS, thyroid imaging reporting and data systems.

with neoplasia in some studies,16,18,22,23,27 we demonstrated this feature to only have significant association with neoplasia and malignancy in univariable analyses and not on multivariable analyses,
similar to Elliott et al findings.16 The presence of abundant colloid and
many lymphocytes in HCP aspirates have been previously shown to

constructed predictive models for neoplasia and malignancy based on

favor NN, including nodular goiter and lymphocytic thyroiditis.16,22

univariable and multivariable stepwise logistic regression analysis of

Our study found the presence of abundant colloid to be associated

statistically significant cytologic, clinical and ultrasound risk factors.

with NN nodules and benign neoplasm, but no statistical significance

The combination of 4 features: high cellularity (moderate to marked),

was achieved due to small number of cases with abundant colloid

non-uniform HC population (anisonucleosis), absence of colloid, and

(9/69). This is explained by the fact that our study only evaluated

nodule size of ≥2.9 cm was found to be a much better predictor of

indeterminate cytologies, and cases containing abundant colloid most

neoplasm and malignancy than has been previously reported.3 Utiliz-

likely were signed out as benign (B-2). However, the absence of col-

ing this four-risk factor model, ROM and RON for indeterminate diag-

loid was significantly associated with neoplasm (Table 3). There was

noses (combined AUS/FLUS-HCT and FN/SFN-HCT) improved from

no significant association between the presence of lymphocytes and

20% to 46% and 49% to 91%, respectively (Tables 1, 6). Even more

the neoplastic or NN nature of the aspirated nodules. Most of our

impressive, was the model's ability to exclude malignancy and neo-

study cohort (61/69 cases), however, had rare or absent lymphocytes

plasm in the absence of those factors. None of 15 patients with zero

in the background, and only one case had numerous lymphocytes

or one out of four risk factors, that is, the absence of four or three risk

(Table 3), limiting our ability to fully evaluate this criterion. However,

factors, had malignancy or neoplasm on surgical follow-up (Table 6)

this is also explained by our study focusing on indeterminate catego-

(Figures 3, 5, 6), resulting in 0% ROM (0/15) and 0% RON (0/15).

ries B-3 and B-4, suggesting that most HCP FNAs with numerous lym-

According to the thyroid Bethesda book, HCP FNA is diagnosed
as FN/SFN-HCT if it's highly cellular with additional supporting fea-

phocytes were signed out as “B-2” at our institution, and thus were
not included in the study population.

tures such as little or no colloid, rare or absent lymphocytes, isolated

Several studies described that HCP aspirates lacking both small-

single cells or three-dimensional (3-D) groups, dysplasia, and trans-

cell dysplasia and large-cell dysplasia (LCD) are almost never

gressing blood vessels (TBV).24 HCP aspirates of low cellularity and

malignant,19,20,22 and those with either small-cell dysplasia or LCD or

minimal colloid, on the other hand, were recommended to be diag-

isolated single cells are associated with HCC.19,22 The Bethesda book

25

nosed as AUS/FLUS.

In an elegant study, constructed in a similar

listed small-cell dysplasia and LCD as important criteria for FN/SFN-

fashion to ours but only evaluated cytologic features, Elliott et al.

HCT, although mentioned that dysplasia (particularly LCD), by itself, is

reported that the combination of absent colloid, absent chronic

an unreliable feature.24 Renshaw et al., on the other hand, stated that
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utilizing anisonucleosis as a criterion, rather than LCD, increased FNA

analysis comparing various thyroid ultrasound imaging classifications

sensitivity for HCC.20 We agree with the latter statement that

found a higher performance of TI-RADS in selecting thyroid nodules

anisonucleosis (non-uniform cell population) has more significance

for FNA.40 Unfortunately, we could not find significant literature

than LCD. Our data showed that LCD was not a significant factor

addressing ATA and TIRADS ultrasound findings in HCP indetermi-

(Figures 1 and 4), as it was expressed at similar rates in malignant

nate lesions. In our study, ATA risk levels and TI-RADS scores

(29%) and benign nodules (29%) (Table 4); and at slightly lower but

achieved significant associations with neoplasm and malignancy only

not statistically significantly different rates in NN (24%) compared to

on univariable analyses. Comparison of the two ultrasound scoring

neoplasm (34%) (Table 3). Due to the low frequency of small-cell dys-

systems demonstrated ATA to be more useful in predicting neoplasia

plasia in our series (3/69 cases), its significance could not be fully eval-

and malignancy, while TI-RADS provided acceptable performance in

uated. Intracytoplasmic lumens (ICL) and TBV have been reported to

identifying malignancy. However, our four-risk factor model signifi-

be associated with neoplasms, and particularly the presence of TBV to

cantly outperformed both ultrasound scoring systems in predicting

be strongly supportive of neoplasm over NN.24 Yang et al., reported

neoplasia (Table 7). Some authors reported that patients with carci-

that TBV was only found in HC neoplasms, and that ICL was detected

noma were typically older, and/or that males carried a higher risk of

in 70% of neoplasms.28 But others considered TBV and ICL, in addition

malignancy,22,29,30,41,42 while others reported no association between

to microfollicular arrangement, isolated single cells, small-cell dysplasia

age32,43 or sex29,32,44 with RON or ROM. Our data found no statisti-

23

and LCD to be non-specific.

Our data demonstrated TBV to be a non-

specific criterion, as it was present in similar proportions in NN

cally significant relationship between age and sex with neoplasia or
malignancy.

vs. neoplastic lesions (41% vs. 43%), and in benign vs. malignant lesions

Finally, there are several potential limitations to our study. First,

(42% vs. 43%) (Tables 3, 4). Many of the NN cases on histologic re-

our analyses were based on a single cohort from a single institution,

section showed areas of hypervascularity within the oncocytic hyper-

therefore introducing potential institutional referral and assessment

plastic nodules, explaining the presence of TBV on corresponding FNAs

biases. Second, we only evaluated cases that had surgical follow-up,

(Figure 4). ICL were seen in 12% and 23% of NN and neoplastic nod-

and there may have been additional clinical features that warranted

ules, respectively; and in 16% and 21% of benign and malignant lesions,

the resection of these nodules, and potentially influencing RON and

respectively, also establishing it as a nonspecific feature (Tables 3, 4).

ROM. Third, cytologic criteria such as small-cell dysplasia was

Increased amount of eosinophilic cytoplasm is often encountered

removed from our analyses as candidate risk predictors due to its low

in PTC, which may mimic HC lesions in FNAs. PTC can be readily rec-

frequency; therefore, its significance as a criterion could not be fully

ognized if PTC nuclear atypia is overt and well-developed, but if it's

evaluated. Fourth, at our institution, per TBSRTC guidelines, B-3 diag-

subtle it may be underdiagnosed as AUS/FLUS-HCT or FN/SFN-HCT.

noses were not subclassified, so we may have not captured all

This may explain why PTCs have been reported in 25–44% of histo-

AUS/FLUS-HCT in our cohort since we only retrieved cases that listed

logically resected malignant HCP lesions.29–31 In our study, oncocytic

“HC” component in the comment or diagnosis lines.

variant of PTC accounted for 36% (5/14) of histologically confirmed

In summary, we identified a combination of 4 features to be

malignant nodules (Table 1). Despite that, we found PTC-like nuclear

strong excluders or predictors of neoplasm and malignancy: nodule

atypia, including powdery chromatin, nuclear enlargement and irregu-

size

larity, and grooves to be of little significance in distinguishing NN from

(anisonucleosis), and absence of colloid. This model was powerful in

neoplastic, benign from malignant, and PTC from HCC (Figure 2 B-C),

excluding neoplasia and malignancy, as the absence of 3 or 4 risk fac-

especially when the atypia is focally present (Tables 3,4). This is prob-

tors established an NPV of 100%. The presence of all 4 factors was

ably explained by the fact that HCs in benign conditions can demon-

associated with a ROM of 46% and RON of 91%, which is a substan-

strate various degrees of nuclear atypia and irregularities mimicking

tial improvement over ROM and RON associated with cytologic diag-

≥2.9

cm,

hypercellularity,

non-uniform

HC

population

24

noses alone. We also found LCD and TGBV to be non-significant

Nodule size appeared to have a significant association with neo-

factors in discriminating NN from neoplasm and malignancy. Further-

plasia and malignancy in several reports.22,29,32–36 In our study, the

more, this four-risk factor model significantly outperformed other

best size cutoff points for neoplasm and malignancy was ≥2.9 cm, sim-

individual or combined clinical and cytologic features and ATA and TI-

ilar to Elliott et al. observations of 2.9 cm as the mean size of HC neo-

RADS ultrasound scoring systems. Additional studies are rec-

plasms.16 Guerrero et al found a nodule size of ≥4 cm to have a 55%

ommended to further validate these findings.

PTC.

association with malignancy,37 while Lee et al suggested tumor size of
≥2.5 cm, hypoechoic nodule and malignant ultrasound features to be
34
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